AMPHANASE

Serial Number 87170982
606

Registration Progress

Application Filed
Sep 14, 2016
Under Examination
Mar 28, 2017
Approved for Publication
Jan 31, 2017
Published for Opposition
Jan 31, 2017
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: AMPHANASE
Previous Owner: Amphastar Pharmaceuticals, Inc.
Classes: 005

Trademark Image

AMPHANASE

Basic Information

Serial Number
87170982
Filing Date
September 14, 2016
Published for Opposition
January 31, 2017
Abandonment Date
March 31, 2020
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Mar 31, 2020
Classes
005

Rights Holder

Amphastar Pharmaceuticals, Inc.

03
Address
11570 Sixth Street
Rancho Cucamonga, CA 91730

Ownership History

Amphastar Pharmaceuticals, Inc.

Original Applicant
03
Rancho Cucamonga, CA

Amphastar Pharmaceuticals, Inc.

Owner at Publication
03
Rancho Cucamonga, CA

Legal Representation

Attorney
Lesley Y. Kim

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

33 events
Date Code Type Description Documents
Jun 2, 2020 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jun 2, 2020 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jul 12, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 11, 2019 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jul 8, 2019 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 11, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jul 8, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 7, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 5, 2019 EX4G S SOU EXTENSION 4 GRANTED Loading...
Mar 5, 2019 EXT4 S SOU EXTENSION 4 FILED Loading...
Mar 5, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 7, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 7, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 26, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 24, 2018 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jul 24, 2018 EXT3 S SOU EXTENSION 3 FILED Loading...
Jul 24, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 31, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 29, 2018 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jan 29, 2018 EXT2 S SOU EXTENSION 2 FILED Loading...
Jan 29, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 31, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 29, 2017 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 29, 2017 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 29, 2017 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 28, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 31, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 31, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 11, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 20, 2016 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 20, 2016 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 19, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 17, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and drug preparations for use in treatment of opioid overdose and addiction; Medicinal preparations for use in treatment of opioid overdose and addiction; Pharmaceutical and drug preparations for the treatment of substance use disorders, addiction, and overdose; Medicinal preparations for the treatment of substance use disorders, addiction, and overdose; Pharmaceutical preparations, namely, opioid antagonists; pharmaceutical preparations, namely, pharmaceuticals which contain the compound naloxone for the treatment of complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids; Pharmaceutical and drug preparations for use in complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005